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Expression proteomics study to 
determine metallodrug targets and 
optimal drug combinations
Ronald F. S. Lee1, Alexey Chernobrovkin2, Dorothea Rutishauser2,3, Claire S. Allardyce1, David 
Hacker4, Kai Johnsson1, Roman A. Zubarev2 & Paul J. Dyson1
The emerging technique termed functional identification of target by expression proteomics (FITExP) 
has been shown to identify the key protein targets of anti-cancer drugs. Here, we use this approach 
to elucidate the proteins involved in the mechanism of action of two ruthenium(II)-based anti-cancer 
compounds, RAPTA-T and RAPTA-EA in breast cancer cells, revealing significant differences in the 
proteins upregulated. RAPTA-T causes upregulation of multiple proteins suggesting a broad mechanism 
of action involving suppression of both metastasis and tumorigenicity. RAPTA-EA bearing a GST 
inhibiting ethacrynic acid moiety, causes upregulation of mainly oxidative stress related proteins. The 
approach used in this work could be applied to the prediction of effective drug combinations to test in 
cancer chemotherapy clinical trials.
Metal based anti-cancer drugs (metallodrugs) are a cornerstone of anti-cancer treatment where platinum drugs, 
such as cisplatin, carboplatin and oxaliplatin, are used as first line treatments for colorectal1, ovarian2, lung3 and 
bladder4 cancers, to name but a few. Based on their success, the development of new generations of metallodrugs 
has been the focus of intense research efforts encompassing various metal centres including ruthenium, rho-
dium, iron, iridium and gold5. It is well known that the use of different metal centres and ligands can tune the 
anti-cancer effects of metallodrugs and help to elucidate the molecular mechanism of drug activity.
Of the various alternatives to platinum-based drugs evaluated to date, ruthenium complexes have advanced 
furthest, with two ruthenium(III)-based compounds, namely indazolium trans-[tetrachlorobis(1H-indazole)
ruthenate(III)] (KP1019) and imidazolium trans-[tetrachloro(dimethylsulfoxide)(1H-imidazole)ruthen-
ate(III)] (NAMI-A), having been evaluated in clinical trials6–10. Ruthenium(III) complexes, however, are prone 
to ligand exchange reactions in aqueous media/physiological buffer which hamper, to some extent, the rational 
design of new compounds with relevant medicinal properties. Consequently, ruthenium(II)-arene compounds 
have attracted considerable attention following encouraging in vivo data on two prototypical compounds, i.e. 
[Ru(η6-p-cymene)Cl(en)]PF6, where en = ethylenediamine11 and [Ru(η6-p-cymene)Cl2(pta)], where pta = 1,
3,5-triaza-7-phosphaadamantane (RAPTA-C)12, 13. RAPTA compounds are active on primary tumors at high 
doses13 or in combination with other drugs12, 14 and they also possess interesting anti-metastatic15 and antiangi-
ogenic16 properties. The pharmacological activity of RAPTA compounds can be tuned through the introduction 
of various functionalities via the arene or PTA moiety17, with a prominent example being a RAPTA derivative 
in which the glutathione transferase inhibitor, ethacrynic acid (EA), is tethered to the arene ring via an amide 
linker18. The resulting compound, termed RAPTA-EA (Fig. 1), is considerably more cytotoxic than RAPTA-C, 
and is a more efficient GST inhibitor than EA alone and shows promising activity against certain breast cancers19.
Due to their very different activity profile compared to cisplatin, the biological targets of RAPTA complexes 
are thought to be proteins and not primarily DNA5. This hypothesis is supported by the observation that cellular 
fractionation of cancer cells exposed to RAPTA complexes show an appreciable amount of ruthenium in cytosolic 
and mitochondrial protein fractions20.
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The nature of the biomolecules that metallodrugs are able to bind to is likely to be diverse21, however, the cel-
lular response to these interactions is usually mediated through changes in relative protein activity. Such changes 
result in both the desired therapeutic effects, but also adverse events which give rise to side-effects. The change can 
also compensate the drugs binding interaction to restore homeostasis leading to resistance. Therefore, proteomic 
methods can be used to monitor the many outcomes of drug binding to chemically diverse targets. Proteomics 
relies on probing targets in whole cells to give a more accurate prediction of clinical usefulness. Measured pro-
tein abundances accounts not only for gene expression, but also for protein degradation and post-translational 
modification, and even reflects subcellular drug distribution. The dynamic range of the cellular proteome, which 
approaches seven orders of magnitude, may be initially limited to approximately 5000 proteins with abundance 
in the mass spectrometric instrumentation range22.
Applying filters to quantitative proteomics data allows proteome-wide drug responses to be elucidated. Filters 
employed include proteome subtraction, scoring, isotope enrichment, cell stage selection and fluorescent tagging, 
each applied singly or in combination. Proteome subtraction methods are probably most common, where the 
data from two experiments, e.g. two related cell lines with a different genotype or phenotype both treated with the 
same drug or the same cell line in the absence of a drug and incubated with a drug, are compared and, only the 
differences analysed. Scoring selects particular proteins based on their known cell function, ordering the signifi-
cance of hits based on what is known about the role of the protein in disease progression, the desired therapeutic 
outcome, or the biological consequences of drug-target interactions. The scoring filter maps the proteome with 
respect to a specific biological response and is therefore, to some extent, like target based screening.
Proteome-wide analysis is particularly challenging to apply in metallodrug studies due to the high incidence 
on non-specific binding. Many metallodrugs will bind to exposed, labile amino acid residues, such as cysteine, 
methionine, glutamate and histidine23. Thus, methods based on affinity purification for protein target screen-
ing, which are extensively used for organic molecules24, are often inconclusive when applied to metallodrugs25. 
Similarly, using proteomics methods, even when multiple filters are applied, identifies multiple hits, some of dubi-
ous significance. These interactions are often non-specific and may also be transient, leading to poor reproduci-
bility. Indeed, two such approaches were performed on RAPTA-type complexes26, 27, without clearly identifying a 
protein target of the drugs evaluated.
In the case of cisplatin, a number of proteomics studies have been performed, the earliest employing E. coli 
cells28. Subsequent studies identified a manageable number of hits from cancer cell lines, i.e. <2029, corresponding 
to proteins involved in a number of pathways, such as cellular energy metabolism, transformation, apoptosis and 
morphologic maintenance, and are therefore difficult to rationalise as targets versus downstream effects. Indeed, 
further experiments have suggested that the relatively low number of hits may have been due to detection limita-
tions and, consequently, as technology improved, proteomics methods shortlisted hundreds of proteins modified 
in cells after cisplatin exposure30. More recently, filtering methods present a manageable number of hits that 
appear significant. However, in many cases the analytical success requires a prior knowledge of the drug target 
and the time-course evolution of the downstream effect. For example, using a combination of isotope labelling 
and cell cycle stage selection, proteomic analysis of cisplatin-induced apoptosis in whole cell lysates identified 26 
proteins significantly upregulated of which the majority of proteins31 identified were known to be linked to apop-
tosis and of these almost half had at least one RNA-binding motif. Another study focused on drug resistance to 
identify protein hits consistent with expression of defence factors that protect cells from drug-induced damage32, 
including the Nrf2 mediated oxidative stress response, mitochondrial processes, protein kinases such as the tar-
gets of rapamycin (mTOR) and AMPK. In addition, specific pathways were changed by cisplatin, including eIF2 
signalling of protein synthesis, actin nucleation via the ARP/WASP complex and regulation of cell polarization33. 
In each case, the data does not differentiate between direct cisplatin targets and downstream events, but indicates 
potential combination therapy objectives that could be used to improve the therapeutic outcome of cisplatin 
treatment, for example, combination therapy with rapamycin34, 35.
Integrating quantitative pathway analysis (qPA) techniques allows the number of hits from filtered pro-
teomics methods to be rapidly scored by relevance. With camptothecin, qPA reduced the number of hits to 
the known camptothecin target, TOPI, from only a handful of putative targets. Importantly, identification was 
Figure 1. Anti-cancer compounds mentioned in this study.
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possible without biasing the analysis towards known targets within the input data36. This method has been 
further advanced by introducing cell cycle stage selection, based on the observation that in late apoptosis the 
abundance change in protein targets of a small-molecule drug appears to be unexpectedly large compared to 
other co-regulated proteins37. The combined method, called Functional Identification of Target by Expression 
Proteomics (FITExP)37, uses protein expression data from at least two different cell lines that are referenced 
against positive controls, to enable the prediction of the most likely protein targets of a small molecule. This 
approach overcomes the limitations associated with standard proteome expression profiling methods in the iden-
tification of protein targets of anti-cancer compounds. In this work, FITExP was used to identify potential protein 
targets of RAPTA-T and RAPTA-EA. Two breast cancer cell lines, invasive MDA-MB-231 cells and non-invasive 
MCF-7 cells, were used in the analysis with paclitaxel and cisplatin as controls with known biological targets 
(Fig. 2).
Results and Discussion
Experimental validation. The FITExP method provides a list of potential drug target hits ranked in order 
of statistical significance with a cutoff of P < 0.05. To validate the reliability of the experimental data generated, 
FITExP analysis was performed with the positive controls paclitaxel and cisplatin, the former known to bind to a 
single protein target and the latter inducing apoptosis via DNA binding. Paclitaxel is a drug that is known to bind 
to tubulin promoting polymerization of microtubules leading to mitotic arrest in cells38. In agreement with this 
mechanism, FITExP analysis identified tubulin beta-6 chain as the only significantly upregulated protein.
Previous proteomic studies of paclitaxel employing selective isotope labelling39 identified several hundred hits 
that were then scored for function. One hit, Programmed Cell Death Protein 4 (PDCD4)40, was highlighted as 
the abundance of this cell-cycle regulated protein had previously been shown to be sufficient to alter paclitaxel 
sensitivity. The mechanism partially involves interactions with Ubiquitin-containing Enzyme E2S (UBE2S), a 
critical protein for mitotic exit41. The importance of PDCD4 was based on reports that show levels of this protein 
are correlated to cancer cell survival in lung cancers and the conclusion suggested the level of this protein could 
be used as a predictive biomarker for paclitaxel-based personalized chemotherapy25.
In the validation of the FITExP technique37 the proteomic analysis of three cell lines (melanoma A375, lung 
cancer H1299 and colon cancer HCT116), identified tubulins and UBE2S as significantly regulated after treatment 
with paclitaxel, which is in line with previous studies identifying tubulins as targets38 and the PDCD4-UBE2S 
pathway modified in response to paclitaxel. Whether the observed UBE2S up-regulation corresponds to a direct 
target or to a downstream effect remains to be determined, nevertheless up-regulation of this protein has been 
implicated in chemotherapy resistance mechanisms and, therefore, its identification suggests that combination 
Figure 2. Schematic of the approach used in this study. For more details concerning the FITExP method refer 
to ref. 37.
www.nature.com/scientificreports/
4Scientific RepoRts | 7: 1590  | DOI:10.1038/s41598-017-01643-1
therapies of paclitaxel and UBE2S inhibitors may be effective. UBE2S is generally highly expressed in breast can-
cer cell lines42, which may explain why it was not identified in the current study.
As mentioned above, the cytotoxic effect of cisplatin primarily involves binding to nucleophilic N-7 sites 
of purine bases in DNA forming interstrand and intrastrand adducts that inhibit DNA replication43. However, 
cisplatin is also known to bind to proteins44 and previous proteomic studies indicate that many proteins are mod-
ified by cisplatin. These proteins mainly comprise molecular chaperones45, 46 and proteins involved in resistance 
mechanisms, including detoxification46 and anti-apoptosis, cell structure29, 46 and DNA transcription45, that is, 
proteins that could be involved in response mechanism to drug toxicity rather than specific targets. FITExP 
analysis identified two significantly upregulated proteins, i.e. receptor tyrosine-protein kinase erbB-2 (ERBB2 or 
HER2/neu) and DNA damage-binding protein2 (DDB2). HER2/neu is the protein product of an oncogene which 
plays an important role in the development of aggressive forms of breast cancer47 and over expression has been 
linked to cisplatin resistance in various cancers in breast and lung cancers48, 49. Cancer chemotherapy regimens 
that combine the anti-HER2/neu antibody, trastuzumab, with cisplatin administration have been shown to be 
clinically efficacious50, 51. It is noteworthy that overexpression of HER2/neu is also linked to paclitaxel resistance48 
and since this protein was not identified in cells treated with paclitaxel it may have a more important role in the 
overall mechanism of cisplatin. The other protein upregulated, i.e. DDB2, is involved in the nucleotide excision 
repair (NER) pathway52. DNA repair pathways have been implicated in the efficacy of cisplatin treatment, e.g. 
reduced levels of DNA repair proteins in testicular cancers are suggested to be linked to the effectiveness of 
cisplatin treatment53, 54 whereas upregulation of DNA repair processes are linked to drug resistance55. NER is a 
principal pathway for removing cisplatin-DNA adducts56 and therefore is likely to be upregulated in response to 
the formation of these adducts, although direct platination of DDB2 could be implicated in the mechanism of 
action of cisplatin.
FITExP analysis of RAPTA-T. As mentioned above, the ruthenium(II) complex, RAPTA-T, is active against 
both primary and metastatic tumors at high doses and, in combination with other drugs, is effective at low doses. 
Moreover, the effects of RAPTA-T are more pronounced on MDA-MB-231 and MCF-7 breast cancer cells and 
have little impact on normal HBL-100 cells derived from breast tissue15.
FITExP analysis of the proteins extracted from RAPTA-T treated MDA-MB-231 and MCF-7 cells was per-
formed using untreated cells and paclitaxel and cisplatin treated cells as controls. Table 1 shows the main proteins 
significantly regulated following the analysis. The top ranked protein is from the phospholipase D (PLD) family of 
enzymes, specifically PLD3. This family of enzymes catalyse the hydrolysis of membrane phospholipids57. PLD3 
is poorly characterised and currently this protein is not linked to cancer progression. However, its transcript 
variants PLD1 and PLD2 have been shown to be involved in the progression of metastatic breast cancers58 and 
isoform-selective inhibitors of specific PLDs were shown to modulate invasiveness in metastatic breast cancer 
models59.
The second ranked protein, MAT2A, catalyses the production of S-adenosylmethionine (SAM - a key methyl 
donor in cellular processes) from methionine and ATP. MAT2A has been shown to be overexpressed in gastric 
cancers60 and its expression inhibition has been shown to significantly supress growth of hepatocellular carci-
nomas61. Specific inhibitors of MAT2A have also been shown to be effective agents against colorectal cancers62. 
Since plasmids for MAT2A are readily available, we expressed recombinant MAT2A to further validate RAPTA-T 
activity on this protein. RAPTA-T exhibited weak binding to MAT2A (IC50 107 ± 13 uM) which indicated its 
significant upregulation is probably a downstream response to perturbations induced by RAPTA-T treatment.
Metallotheinins (MTs) are a class of proteins with high content of cysteine residues that are responsible for 
detoxifying heavy metals, and high levels of MT expression has been associated with poor clinical outcomes of 
cancer patients undergoing therapy with platinum based metallodrugs63. MT2 has been previously shown to bind 
to RAPTA-C (Fig. 1), an analogue of RAPTA-T with a closely related biological profile64. The binding interaction 
displaces the zinc ion suggesting involvement of key Cys residues. Zing finger HIT (zf-HIT) are sequence motifs 
found in various proteins and contain conserved cysteine and histidine residues that can coordinate zinc atoms65. 
Protein Acronym P-value Regulation
Phospholipase D3 PLD3 9.11E-04 Up
S-adenosylmethionine 
synthase isoform type-2 MAT2A 1.11E-03 Up
Metallothionein-2 MT2A 2.33E-03 Up
Zinc finger HIT domain-
containing protein 2 ZNHIT2 1.39E-02 Up
RNA-binding protein 47 RBM47 1.86E-02 Up
Pyruvate dehydrogenase 
phosphatase catalytic 
subunit 1, mitochondrial
PDP1 3.56E-02 Up
Chromatin target of 
PRMT1 protein CHTOP 4.01E-02 Up
Chromosome transmission 
fidelity protein 8 homolog 
isoform 2
CHTF8 4.37E-02 Up
Table 1. Proteins significantly regulated following RAPTA-T treatment determined from FITExP analysis of 
MCF-7 and MDA-MB-231 cells.
www.nature.com/scientificreports/
5Scientific RepoRts | 7: 1590  | DOI:10.1038/s41598-017-01643-1
These motifs are suggested to play important roles in gene regulation and chromatin remodelling. It was shown 
previously that RAPTA complexes bind proteins with zinc finger domains25 to displace the zinc ion64.
RNA binding proteins (RBMs) are proteins that bind to single or double stranded RNA and play a role in 
post-transcriptional control of RNAs, such as splicing, mRNA stabilization, mRNA localization and transla-
tion66. RBM47 has been shown to play an important role in metastatic breast cancers, where low expression of 
this protein is associated with highly metastatic phenotype67. Furthermore, RMB47 knockout mice xenografted 
with lung adenocarcinomas were show enhanced tumor formation and metastasis68. It is possible that treatment 
with RAPTA-T activates compensatory pathways causing increased expression of RMB47 that could be linked to 
anti-metastatic activity.
The pyruvate dehydrogenase (PD) complex converts pyruvate into acetyl-CoA, a substrate used in the citric 
acid cycle for cellular respiration69. Pyruvate dehydrogenase phosphatases (PDPs) in the mitochondria catalyze 
the dephosphorylation and reactivation of the alpha subunit of the E1 component of the PD complex70. PDP1 has 
been implicated in promoting the Warburg effect and growth in tumors such that it has been identified as a key 
anti-cancer target71. In vitro studies of the cellular effects of RAPTA-T have shown that the compound accumu-
lates appreciably in the mitochondria and perturbs the expression of a large number of mitochondrial proteins, 
including overexpression of ATP synthetase27, an enzyme heavily involved in cellular respiration.
Protein arginine methyltransferases (PRMTs) catalyse the process of arginine methylation, a widespread 
post-translational modification in eukaryotic cells. PRMTs use S-adenosyl-L-methionine as the methyl donor, 
which is also a product of MAT2A. The chromatin target of PRMT1 protein (CHTOP) is a chromatin associated 
protein that has been shown to be critical for estrogen-dependent gene activation72 and is also implicated in the 
tumorigenicity of glioblastoma cells73. Considering that RAPTA-C is known to bind to histones74, 75, a component 
of chromatin, and could be a binding partner to MAT2A, it is possible that its activity also perturbs expression 
of CHTOP.
The chromosome transmission fidelity factor 8 (CTF8) is a chromosome cohesion protein involved in sister 
chromatid cohesion and fidelity of chromosome transmission76. It has been implicated in DNA replication and 
repair pathways and has been shown to have reduced expression in renal and prostate tumors57. Since it is a 
nuclear protein associated with chromatin its upregulation as a response to RAPTA-T binding to chromatin is 
likely, although direct RAPTA-T binding cannot be excluded.
FITExP analysis of RAPTA-EA. RAPTA-EA is composed of the main ruthenium(II) arene fragment pres-
ent in RAPTA-T, but with an ethacrynic acid (EA) moiety tethered to the arene ring (Fig. 1). EA is an inhibitor of 
glutathione transferases (GSTs), which are involved in the removal of exogenous substances such as cancer chem-
otherapeutic agents77, and the compound was designed to overcome GST-based resistance. Notably, GSTP1‐1 
is often overexpressed in solid tumors following exposure to anti-cancer drugs78. RAPTA-EA shows in vitro 
GST inhibition levels superior to that of EA alone18 and has a much higher differential cytotoxicity than simple 
RAPTA-type complexes in breast cancer cell lines19. FITExP analysis was used to identify the main proteins 
regulated from RAPTA-EA treatment (Table 2). Interestingly, these hits are different from those identified with 
RAPTA-T treatment, suggesting the single ligand substitution dominates the biological effect.
The top protein, heat shock 70 kDa protein 1A/1B (HSPA 1A/1B), belongs to the heat shock protein (HSP) 
class, which are ubiquitous and conserved proteins that act as molecular chaperones to promote correct protein 
folding and trafficking70. Some HSPs are expressed constitutively, whereas others are induced in response to spe-
cific stress79 and have hence been identified as potential drug targets80, 81. Inhibition of HSP90 has been shown to 
have anticancer activity; in contrast, induction of HSP70 has been linked to recovery from, for example, ischemic 
heart disease, diabetes and neurodegeneration82, 83. However, HSP70 is not thought to be an ideal drug target as 
reducing HSP70 activity via down-regulation can be compensated84. DnaJ homolog subfamily B member 4 is also 
a HSP that functions as both a chaperone and tumor repressor protein mainly involved in the targeting and deg-
radation of the cell adhesion protein E-cadherin57. Supporting the role of HSPs in the mechanism of RAPTA-type 
compounds, previous non-specific proteome profiling identified HSPs as likely candidates27 and HSPA 1A/1B 
overexpression has been observed in MCF-7 cells treated with RAPTA-EA85.
Heme oxygenase 1 (HMOX 1) is an enzyme which cleaves heme at the alpha methane bridge forming biliv-
erdin and is involved in hematopoesis. It is also a marker of oxidative stress, and deficiency in this protein 
results in impaired stress hematopoiesis resulting in marked erythrocyte fragmentation, coagulation abnormal-
ities, and iron deposition in renal and hepatic tissues86. Exposure to EA has been previously shown to result in 
Protein Acronym P-value Regulation
Heat shock 70 kDa protein 1A/1B HSPA 1A/1B 2.46E-05 Up
Heme oxygenase 1 HMOX1 7.44E-05 Up
TRAF-type zinc finger domain-containing protein 1 TRAFD1 5.94E-04 Up
Sulfiredoxin-1 SRXN1 2.17E-03 Up
Thioredoxin reductase 1, cytoplasmic TXNRD1 2.21E-02 Up
DnaJ homolog subfamily B member 4 DNAJB4 3.52E-02 Up
Flavin/biliverdin reductase (NADPH) BLVRB 4.47E-02 Up
Glucose-6-phosphate 1-dehydrogenase G6PD 4.48E-02 Up
Table 2. Proteins significantly regulated following RAPTA-EA treatment determined from FITExP analysis of 
MCF-7 and MDA-MB-231 cells.
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elevated expression of this protein87, suggesting that the observed regulation of this protein is due to the pres-
ence of the EA moiety. Flavin/biliverdin reductase was also identified and is an oxidoreductase that catalyses 
the NADPH-dependent reduction of biliverdin to bilirubin70, the next step in heme catabolism. Thus, it is not 
surprising to find co-regulation of this related protein in RAPTA-EA treated cells.
Sulfiredoxin-1 (SRXN1) contributes to oxidative stress resistance by reducing cysteine-sulfinic acid formed 
by exposure to oxidants into peroxiredoxins. As both HMOX1 and SRXN1 play a role in oxidative stress and 
have been shown to be co-regulated in cells exposed to anti-cancer compounds88, their upregulation is likely to 
be due to EA. Glucose-6-phosphate 1-dehydrogenase, is a cytosolic protein whose main role is the production 
of NADPH an electron donor in the defence against oxidising agents and in reductive biosynthetic reactions57. 
Deficiency in this protein in humans can cause neonatal jaundice and haemolysis upon exposure to oxidative 
stress and therefore its upregulation is likely to be linked to the cytotoxicity of RAPTA-EA. Thioredoxin reduc-
tase 1 reduces thioredoxins and other substrates and plays a role in selenium metabolism and protection against 
oxidative stress57. Depletion of GST activity is correlated to increased levels of oxidative stress response89, poten-
tially leading to upregulation of this protein. TRAF-type zinc finger domain-containing protein 1 is a negative 
feedback regulator that controls excessive immune response in vertebrates90. Though not expected to be a target 
of RAPTA-EA, it was shown in previous studies that RAPTA-type complexes can bind to proteins containing 
zinc-finger domains possibly perturbing the regulation of this protein25.
Implications of the FITExP analysis of RAPTA-T and RAPTA-EA. Proteins upregulated by 
RAPTA-EA treatment were mostly related to oxidative stress responses presumably as a result of GST inhibition 
by the EA moiety. Since GST levels itself were not significantly modified, and GST inhibition by RAPTA-EA has 
been demonstrated in vitro18, it seems likely that these proteins are not direct targets. This would certainly seem 
to be the case for the proteins significantly regulated by cisplatin treatment. Cisplatin binds to DNA and regulated 
proteins are associated with DNA repair pathways, suggesting downstream effects in response to DNA binding. 
RAPTA-T shows a plethora of upregulated proteins, many of which correlate well with its toxicity to primary and 
metastatic tumors.
The proteins identified in these studies help to elucidate the molecular mechanism of candidate drug com-
plexes and, importantly, should help to select other drugs that could be used in combination with them. For 
example, we showed that cisplatin treated cells upregulate HER2/neu which is implicated in cisplatin resistance, 
and cisplatin is used in the clinic in combination with trastuzumab, a HER2/neu inhibitor. Consequently, the 
application of RAPTA-T or RAPTA-EA in combination with known inhibitors of the key hit proteins identified 
in this study could be lead to effective drug combinations. From a therapeutic standpoint, RAPTA-EA could be 
explored in cancers where EA alone has shown potency, such as chronic lymphocytic leukemias91, or where EA 
combined with another agent shows synergy, such as the combination of EA with afatinib, an irreversible epi-
dermal growth factor receptor tyrosine kinase inhibitors for breast cancers92. On the other hand, due to its broad 
mechanism of action, RAPTA-T could potentially be more useful if used concomitantly with drugs that target 
specific cancer pathways and could also play a role in therapies for later stage cancers due to its anti-metastatic 
properties.
Conclusions. Here, application of the FITExP allowed us to gauge potential drug targets and mechanistic 
pathways involved in the action of two novel ruthenium(II) metallodrugs with very different phenotypic charac-
teristics and from this knowledge infer their role in therapy. RAPTA-T treatment leads to upregulation of multiple 
proteins suggesting a broad mechanism of action involving suppression of both metastasis and tumorigenicity. In 
contrast, proteins upregulated upon incubation with RAPTA-EA are linked to regulation of the oxidative stress 
response and are therefore thought to be conferred by the EA moiety in the drug. Potentially, future application 
of the FITExP approach in this manner could be useful for identification of cancer chemotherapy drug combi-
nations, where commonly cancer clinical trials fail at phase II where drug combinations are first tried and tested.
Methods
Materials. RAPTA-T93 and RAPTA-EA18 were prepared using literature methods. All other compounds, rea-
gents were purchased from commercial sources and used without further purification.
Cell maintenance, treatment and preparation for expression profiling. MDA-MB-231 (human 
mammary gland adenocarcinoma) and MCF-7 (human mammary gland adenocarcinoma cells) were obtained 
from the European Collection of Cell Cultures (Salisbury, UK). Cells were cultured in DMEM Glutamax medium 
supplemented with 10% fetal calf serum, penicillin 100 units/mL Streptomycin 100 µg/mL (Invitrogen). Cells 
were incubated at 37 °C in a moist environment containing 5% CO2. For proteomic expression experiments, cells 
were seeded at a density of 5 × 105 cells in a 6-well plate for 24 h. Media was aspirated and cells were rinsed with 
1X PBS before addition of fresh media containing solutions of compound (Paclitaxel, Cisplatin, RAPTA-EA and 
RAPTA-T, dosed at a concentration to achieve a cell kill of approximately 50% after 48 h). After 48 h, cells were 
detached with enzyme free cell dissociation solution and centrifuged at 200 G for 5 min. Cell pellets were snap 
frozen in liquid N2 and stored at −80 °C before sample preparation for mass spectrometry. All cell experiments 
were carried out in triplicate.
Protein digestion. Breast cancer cell pellets were thawed on ice and depending on the number of cells/pellet 
reconstituted in 100–200 µl 8 M Urea with 100 mM NaCl. Cells were disrupted by probe sonication (Vibra-Cell™ 
CV18, Sonics & Materials, Newtown, USA) two times for 5/5 s cycles over 20 s followed by centrifugation at 
12,000 rpm for 10 min at 4 °C. Solubilized proteins were transferred to fresh vials and the protein concentrations 
were determined using microBCA from Pierce (Thermo Fisher Scientific Inc). From each sample 10 µg extracted 
protein were dissolved in a final concentration of 0.1% ProteaseMax (Thermo Fisher Scientific Inc), 50 mM 
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ammonium bicarbonate and 10% acetonitrile in a total volume of 80 µl. The resulting protein solutions were 
incubated for 45 min at 37 °C while shaking followed by an additional sonication of 10 min at room temperature. 
Samples were centrifuged and directly subjected to a tryptic digestion protocol carried out by a liquid handling 
robot (MultiProbe II, Perkin Elmer). This included protein reduction in 5 mM DTT at 56 °C and alkylation in 
15 mM iodacetamide for 30 min at room temperature in the dark. Trypsin was added in an enzyme to protein 
ratio of 1:30 and digestion was carried out over night at 37 °C. Samples were acidified by adding 6 µl concentrated 
formic acid, incubated for 30 min at room temperature and centrifuged for 20 min at 3000 rpm in order to remove 
undigested material.
LC-MS/MS. Tryptic peptides were cleaned with C18 StageTips (Thermo Fisher Scientific Inc) and the result-
ing peptide mixture was injected into a nano-Ultimate system (Thermo Scientific, Bremen, Germany) coupled to 
a Q Exactive mass spectrometer (Thermo Scientific, Bremen, Germany). The chromatographic separation of the 
peptides was achieved using a 28 cm long in-house packed column (C18-AQ ReproSil-Pur, Dr. Maisch GmbH, 
Germany) with the following gradient: 4–26% acetonitrile in 120 min, 26–95% ACN for 5 min and 95% ACN for 
5 min all at a flow rate of 300 nl/min. The MS acquisition method was comprised of one survey full scan ranging 
from m/z 300 to m/z 1650 acquired with a resolution of R = 140,000 at m/z 200 and a target value of 5 × 106, 
followed by data-dependent higher-energy collisional dissociation fragmentation scans from maximum sixteen 
most intense precursor ions with a charge state ≥2. Sequencing was performed with a target value of 2 × 105 ions 
determined with predictive automatic gain control, for which the isolation of precursors was performed with a 
window of 4 m/z. Scans were acquired with a resolution of R = 17,500 and normalized collision energy was set 
to 26.
Data processing. Fragmentation spectra were extracted using Raw2MGF (in-house developed software) and 
the resulting mascot generic files were searched against a SwissProt protein database (reversed protein sequences 
had been added to database for decoy search) using the Mascot 2.3.0 (Matrix Science Ltd.). Mascot was set up 
to search a concatenated SwissProt protein database (selected for Homo sapiens) with enzyme specificity set as 
C-terminal to arginine and lysine, allowing cleavage before proline and a maximum of two missed cleavage sites. 
The allowed peptide mass deviation was set to 10 ppm and 0.02 Da for the fragment ions. Carbamidomethylation 
of cysteine was specified as a fixed modification, whereas oxidation of methionine, N-terminal protein acetylation 
and deamidation of asparagine and glutamine were defined as variable modifications.
Quantitative information was extracted using in-house developed label-free software Quanti v.2.5.3.194. Only 
reliably identified (FDR < 0.01), unmodified peptides with unique sequences were considered and only proteins 
discovered with at least two such peptides were quantified. For each protein, one database identifier (ID) was 
selected, covering all the peptide sequences identified for this specific protein. If two proteins belonging to differ-
ent protein groups had a partial sequence overlap, then all the peptides belonging to this overlap were ignored. 
The results were reported as a set of relative protein abundances A scaled such that the geometric mean of the 
abundance of each protein over all samples was 1.0.
Scoring system. For combining the data from replicate analysis, “medians of ratios” are used instead of 
“ratios of medians”, as has previously been suggested95. If relative protein abundance of i-th quantified protein in 
c-th cell line under j-th treatment is denoted as Ai j
c
, , then regulation Reg is calculated as:
=






Reg Median
A
A
log ,
(1)
i j
c i j
c
i
c,
,
,0
and specificity Spec is defined as:
=






≠Spec Median
A
A
log ,
(2)
i j
c
k j
i j
c
i k
c,
,
,
where j = 0 corresponds to untreated cells for Reg calculation, and j≠k for Spec calculations.
Exceptional behaviour measure. For each I-th protein and each J-th drug treatment, two vectors were 
calculated:
=⁎ ( )C Reg RegCorr , , (3)iI i jc I jc, , ,
= ≠ ≠( )C Reg RegCorr , , (4)iI J i j Jc I j Jc, , ,
where ∗Ci
I ,  are the Pearson’s correlation coefficients of expression profiles over all treatments of i-th and I-th pro-
teins, while Ci
I J, are correlation coefficients of the expression profiles of i-th and I-th proteins excluding treatment 
J. Then, the linear model ∗~C Ci
I
i
I J, , was created and the coefficient of determination of the model was used to 
calculate the measure of exceptional behavior ExcI,J of I-th protein under J-th treatment:
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=Exc
R
1
(5)
I J
I J
,
2
,
Calculation of p-values. In estimation of the p-value of a protein with a certain rank, we used the rank 
product method, which has previously been found to be robust and tolerant to missing values in detection differ-
entially regulated genes in replicated experiments96. The method has also been successfully applied to proteomics 
datasets for detection of significantly regulated proteins97. In adaptation of the method by Schwämmle et al., the 
Reg, Spec and Exc ranks were treated as independent variables, and their values for different cell lines as well as at 
different incubation times were considered as independent replicate measurements. The rank product was con-
sidered to have a gamma distribution under null hypothesis, from which the p-values for the set of ranks of every 
protein were calculated. Adjusted p-values were calculated using standard Bonferroni correction using the total 
number of proteins as a multiplication factor.
Availability of data. The mass spectrometry proteomics data have been deposited at the ProteomeXchange 
Consortium via the PRIDE98 partner repository with the dataset identifier PXD005766.
Recombinant protein expression. Human MAT2A plasmid was obtained from Addgene (www.addgene.
org, plasmid #53648) as a bacterial stab. Plasmid DNA was amplified in antibiotic-containing media and 
extracted with a plasmid miniprep kit (Qiagen, Basel, Switzerland) according to the manufacturer’s instructions 
and sequenced for validation. The plasmid was transformed into competent E. coli strain BL21 (DE3) Rosetta and 
selected with ampicillin. One colony was picked from the LB agar plate and used to inoculate a 10 mL culture of 
LB medium with ampicillin. The culture was grown overnight at 37 °C with agitation at 150 rpm in an incubator 
shaker. Next, the 10 mL culture was used to inoculate a 1 L culture of LB medium and ampicillin. The culture was 
incubated at 37 °C with agitation as before until an optical density of 0.6 was reached at a wavelength of 600 nm. 
The temperature of the incubator shaker was then reduced to 16 °C, and IPTG was added to the culture to a final 
concentration of 1 mM. The culture was allowed to incubate overnight at 16 °C. Next, the culture was centrifuged 
at 3,500 rpm for 20 min, and the cell pellets were maintained frozen at −80 °C. The frozen cell pellet was allowed 
to thaw and was re-suspended in 60 mL of binding buffer (150 mM NaCl and 25 mM sodium phosphate (pH 7.3)) 
containing a protease inhibitor cocktail (Roche Diagnostics, Rotkreuz, Switzerland). The resuspended cells were 
sonicated during 8 cycles of 20 s. The solution was then centrifuged at 11,000 rpm for 30 min. The supernatant 
was retained and imidazole was added to 10 mM. Then 2 ml of FastFlow IMAC beads (GE Healthcare, Glattbrugg, 
Switzerland) were added. The solution was mixed by rotation for 1 h at 4 °C. The resin was transferred to a dis-
posable column (Bio-Rad, Crissier, Switzerland) and washed with 10 column volumes (CVs) of binding buffer 
with 10 mM imidazole. Next, the column was washed sequentially with 10 CVs of binding buffer with 25 mM 
imidazole, 5 CVs of binding buffer with 50 mM imidazole, and 5 CVs of binding buffer with 100 mM imidazole. 
The protein was then eluted with 4 × 2 CVs of binding buffer with 250 mM imidazole. The washes and elutions 
were analyzed by reducing SDS-PAGE. The fractions with the recombinant protein were pooled and dialyzed 
twice against 2 L of PBS. After dialysis the concentration of the protein was determined by absorbance at 280 nm.
MAT2A enzymatic assays. Recombinant human MAT2A stored in 50% glycerol was dialysed into MAT2A 
buffer containing 50 mM MOPS at pH 7.4, 50 mM potassium acetate, 20 mM magnesium acetate. All substrates 
and compounds used were dissolved in MAT2A buffer. MAT2A was pre-incubated with different concentra-
tions of RAPTA-T (1000, 500, 250, 125, 62.5, 31.3, 15.6, 7.8 and 0 µM) at various time-points at 37 °C. 50 µM 
L-methionine and 1 mM ATP were added to start the reaction. Final reaction volumes were fixed at 150 µL. After 
30 min, reactions were quenched with 5 µL acetic acid and cooled on an ice pellet. 25 µL of sample was used for a 
phosphate colorimetric assay (Sigma-Aldrich, MAK030) according to the manufacturer’s instructions, and the 
IC50 values were calculated in Graphpad Prism version 6.00 for Windows. The IC50 values reported were the mean 
of two independent experiments.
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